On Jul. 16, 2020, Atossa Therapeutics announced that it has contracted with Avance Clinical to conduct a clinical study of Atossaﾒs proprietary drug candidate AT-301, to be administered by nasal spray. Avance is a leading Australian clinical research organization and has successfully completed multiple clinical studies of Atossaﾒs proprietary Endoxifen.

AT-301 is Atossaﾒs proprietary formula intended for nasal administration in patients immediately following diagnosis of COVID-19 but who have not yet exhibited symptoms severe enough to require hospitalization.